Navigation Links
Cell Therapeutics, Inc.'s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
Date:12/10/2012

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ: CTIC and MTA: CTIC) today announced that its Board of Directors has approved certain amendments to CTI's existing shareholder rights plan ("Rights Plan") to decrease the exercise price of the preferred stock purchase rights ("Rights") under the Rights Plan from $14.00 to $8.00 and to extend the "final expiration date" from the close of business on the third anniversary of January 7, 2010 (the "Record Date"), to the close of business on December 3, 2015.  The Rights were initially distributed as a dividend on each share of CTI's common stock outstanding on the Record Date and currently trade with each outstanding share of CTI's common stock.

About Cell Therapeutics, Inc.

Cell Therapeutics (Nasdaq and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcomes of which could materially and/or adversely affect actual future results and the market price of CTI's securities, including, but not limited to, statements regarding amendments to CTI's Rights Plan. Specifically, the risks and uncertainties include that CTI cannot guarantee that the Rights Plan, as amended, will deter any coercive takeover tactics; CTI's ability to continue to raise capital as needed to fund its operations; risks related to competitive factors, technological developments, costs of developing, producing, and selling CTI's product candidates; and the risk factors listed or
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
4. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
5. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
6. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
7. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
8. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
9. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
10. GenturaDx Announces Formation of Scientific Advisory Board
11. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... 15, 2011 Reportlinker.com announces that a ... its catalogue: India Biotechnology ... http://www.reportlinker.com/p0553099/India-Biotechnology-in-India-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Disc This report analyzes ... US$ million by the following Key Sectors ...
... NEW BRUNSWICK, N.J., June 14, 2011 Psoriasis is ... of the world,s population or more than 125 million ... others, it is disabling. On a continuing ... an article published in the Journal of Investigative ...
... Inc. , a California-based clean technology company serving the ... yeast technology from the USDA Forest Products Laboratory (FPL) ... the fermentation of C5 sugars, such as xylose, to ... Cooperative Research and Development Agreement (CRADA) between FPL and ...
Cached Biology Technology:Reportlinker Adds India Biotechnology in India Industry 2Reportlinker Adds India Biotechnology in India Industry 3Reportlinker Adds India Biotechnology in India Industry 4Reportlinker Adds India Biotechnology in India Industry 5Reportlinker Adds India Biotechnology in India Industry 6Reportlinker Adds India Biotechnology in India Industry 7Reportlinker Adds India Biotechnology in India Industry 8Reportlinker Adds India Biotechnology in India Industry 9Reportlinker Adds India Biotechnology in India Industry 10Reportlinker Adds India Biotechnology in India Industry 11Reportlinker Adds India Biotechnology in India Industry 12Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment 2EdeniQ Licenses Yeast Technology from USDA 2
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... marginal division of the striatum is also involved ... degree of substance P in the striatal marginal ... and his team, College of Biophotonics, South China ... substance P receptor, neurokinin 1 was highly expressed ... normal rats. Unilateral or bilateral injection of an ...
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2Blame it on the astrocytes 2
... French . Researchers at the Montreal ... basis of depression in male athletes with persisting post-concussion ... Archives of General Psychiatry, has important clinical implications for ... concussion. Depression is one of a number ...
... release is also available in German . ... modified bacteria produce human insulin. In future, gene therapy should ... a diseased organism so that they can address deficiencies to ... to work, foreign (or synthetic) DNA must be introduced into ...
... the interaction of genes and environment in the ... King,s College London, has been awarded the Mortimer ... Developmental Psychobiology. Presented jointly by the Sackler Institute ... and the Sackler Institute for Developmental Psychobiology at ...
Cached Biology News:MNI researchers locate neurological basis of depression following sports concussion 2Cells get sprayed 2Research pioneer in the developmental origins of psychiatric illness is awarded the Sackler prize 2
MHC Volumes 1 & 2...
BD IMagnet 1 each...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
... M.W. Turner (1997). • This book ... in the production of high-quality antibodies, ... the standardisation of antibodies and antigens, ... systems, enzyme immunoassays for detecting cell-surface ...
Biology Products: